Avalo Therapeutics (AVTX) Total Liabilities (2014 - 2026)

Avalo Therapeutics has reported Total Liabilities for 13 years, with the latest figure at $31.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 98.42% year-over-year to $31.6 million; the trailing twelve-month figure through Mar 2026 stood at $31.6 million (up 98.42% YoY), and the FY2025 full-year result was $33.4 million, up 88.75% from the prior year.
• Total Liabilities for Q1 2026 stood at $31.6 million, down from $33.4 million in the prior quarter.
• The five-year high for Total Liabilities was $224.8 million in Q1 2024, with the low at $13.7 million in Q4 2023.
• Historically, Total Liabilities has averaged $49.6 million across 5 years, with a median of $33.6 million in 2025.
• Annual changes were most pronounced in 2024 — Total Liabilities surged 428.95% — and 2025, when it slumped 92.92%.
• Avalo Therapeutics' Total Liabilities stood at $44.3 million in 2022, then sank by 69.09% to $13.7 million in 2023, then grew by 29.3% to $17.7 million in 2024, then soared by 88.75% to $33.4 million in 2025, then decreased by 5.52% to $31.6 million in 2026.
• The last three Total Liabilities figures came in at $31.6 million (Q1 2026), $33.4 million (Q4 2025), and $33.6 million (Q3 2025), per Business Quant data.